Chemotherapy IS_A_TYPE_OF CancerTreatment
Chemotherapy USES Anti-cancerDrugs
Anti-cancerDrugs ARE ChemotherapeuticAgents
Anti-cancerDrugs ARE AlkylatingAgents
Chemotherapy IS_A_TYPE_OF ChemotherapyRegimen
Chemotherapy MAY_BE_GIVEN_WITH CurativeIntent
CurativeIntent INVOLVES CombinationsOfDrugs
Chemotherapy MAY_AIM_TO ProlongLife
Chemotherapy MAY_AIM_TO ReduceSymptoms
Chemotherapy IS_A_TYPE_OF MajorCategoriesOfMedicalDiscipline
MedicalDiscipline DEVOTED_TO PharmacotherapyForCancer
PharmacotherapyForCancer IS_CALLED MedicalOncology
TermChemotherapy IS_CALLED Non-specificUsageOfIntracellularPoisonsToInhibitMitosis
IntracellularPoisons INHIBIT Mitosis
IntracellularPoisons INDUCE DnaDamage
DnaDamage INDUCE Chemotherapy
InhibitionOfDnaRepair CAN_AUGMENT Chemotherapy
ConnotationOfWordChemotherapy EXCLUDES MoreSelectiveAgents
MoreSelectiveAgents BLOCK ExtracellularSignals
DevelopmentOfTherapies HAVE SpecificMolecularOrGeneticTargets
SpecificMolecularOrGeneticTargets INHIBIT Growth-promotingSignals
Growth-promotingSignals FROM ClassicEndocrineHormones
OtherInhibitionsOfGrowth-signals ASSOCIATED_WITH ReceptorTyrosineKinases
ReceptorTyrosineKinases REFERRED_TO_AS TargetedTherapy
UseOfDrugs INVOLVES SystemicTherapy
UseOfDrugs INTRODUCED_INTO BloodStream
UseOfDrugs ABLE_TO_ADDRESS CancerAtAnyAnatomicLocation
SystemicTherapy USED_IN_CONJUNCTION_WITH OtherModalities
OtherModalities CONSTITUTE LocalTherapy
LocalTherapy EFFICACY_IS_CONFINED_TO AnatomicArea
LocalTherapy FOR Cancer
LocalTherapy INCLUDE RadiationTherapy
LocalTherapy INCLUDE Surgery
LocalTherapy INCLUDE HyperthermiaTherapy
TraditionalChemotherapeuticAgents ARE Cytotoxic
TraditionalChemotherapeuticAgents INTERFERING_WITH CellDivision
CancerCells VARY_WIDELY_IN SusceptibilityToTheseAgents
Chemotherapy CAN_BE_THOUGHT_OF_AS WayToDamageOrStressCells
WayToDamageOrStressCells INDUCE CellDeath
Apoptosis INDUCE Cells
SideEffectsOfChemotherapy INDUCE DamageToNormalCells
NormalCells VARY_WIDELY_IN Anti-mitoticDrugs
CellsInTheBoneMarrow VARY_WIDELY_IN Chemotherapy
CellsInTheDigestiveTract INVOLVES Chemotherapy
CellsInTheHairFollicles ARE_AFFECTED_BY Chemotherapy
SideEffectsOfChemotherapy INDUCE Myelosuppression
Myelosuppression DECREASED_PRODUCTION_OF BloodCells
Myelosuppression ALSO_CAUSES Immunosuppression
SideEffectsOfChemotherapy INDUCE Mucositis
Mucositis INFLAMMATION_OF LiningOfTheDigestiveTract
SideEffectsOfChemotherapy ALSO_CAUSES Alopecia
ChemotherapyDrugs FIND_USE_IN HostOfDiseases
Diseases RESULT_FROM HarmfulOveractivityOfTheImmuneSystem
HarmfulOveractivityOfTheImmuneSystem AGAINST Self
Diseases INCLUDE RheumatoidArthritis
Diseases INCLUDE SystemicLupusErythematosus
Diseases INCLUDE MultipleSclerosis
Diseases INCLUDE Vasculitis
There ARE NumberOfStrategies
NumberOfStrategies IN AdministrationOfChemotherapeuticDrugs
AdministrationOfChemotherapeuticDrugs USED_IN Today
Chemotherapy MAY_BE_GIVEN_WITH CurativeIntent
Chemotherapy MAY_AIM_TO ProlongLife
Chemotherapy MAY_AIM_TO PalliateSymptoms
ChemotherapyRegimens REQUIRE Recipient
Recipient REQUIRE Treatment
PerformanceStatus IS_OFTEN_USED_AS Measure
Measure IS_OFTEN_USED_AS Person
Person IS_OFTEN_USED_AS Chemotherapy
Person DOSE_REDUCTION_IS_REQUIRED Chemotherapy
FractionOfCells DIE_WITH Treatment
Doses MUST_BE_ADMINISTERED_TO_CONTINUE_TO_REDUCE SizeOfTumor
ChemotherapyRegimens APPLY DrugTreatment
DrugTreatment IN_CYCLES ChemotherapyRegimens
FrequencyOfTreatments LIMITED_BY Toxicity
DurationOfTreatments LIMITED_BY Toxicity
EffectivenessOfChemotherapy ARE_AFFECTED_BY TypeOfCancer
EffectivenessOfChemotherapy ARE_AFFECTED_BY Stage
OverallEffectiveness VARY_WIDELY_IN BeingCurativeForSomeCancers
OverallEffectiveness VARY_WIDELY_IN BeingIneffectiveForSomeBrainTumors
OverallEffectiveness VARY_WIDELY_IN BeingNeedlessInOthers
SomeLeukemias ARE SomeCancers
SomeBrainTumors ARE SomeBrainTumors
MostNon-melanomaSkinCancers ARE Others
DosageOfChemotherapy CAN_BE Difficult
DosageOfChemotherapy INVOLVES CalculatedBodySurfaceArea
CalculatedBodySurfaceArea INVOLVES MathematicalFormula
CalculatedBodySurfaceArea INVOLVES Nomogram
MathematicalFormula USED_IN Recipient'sWeightAndHeight
Nomogram INVOLVES Recipient'sWeightAndHeight
MathematicalFormula RATHER_THAN_BY DirectMeasurementOfBodyArea
Nomogram RATHER_THAN_BY DirectMeasurementOfBodyArea
Formula ORIGINALLY_DERIVED_IN 1916Study
1916Study ATTEMPTED_TO_TRANSLATE MedicinalDosesEstablishedWithLaboratoryAnimalsToEquivalentDosesForHumans
1916Study INCLUDED NineHumanSubjects
Chemotherapy ORIGINALLY_DERIVED_IN 1950s
BsaFormula ADOPTED_AS OfficialStandardForChemotherapyDosing
OfficialStandardForChemotherapyDosing FOR_LACK_OF BetterOption
ValidityOfMethod HAS_BEEN_QUESTIONED_BECAUSE FormulaOnlyTakesIntoAccountWeightAndHeight
DrugAbsorptionAndClearance ARE_INFLUENCED_BY MultipleFactors
MultipleFactors INCLUDE Age
MultipleFactors INCLUDE Sex
MultipleFactors INCLUDE Metabolism
MultipleFactors INCLUDE DiseaseState
MultipleFactors INCLUDE OrganFunction
MultipleFactors INCLUDE Drug-to-drugInteractions
MultipleFactors INCLUDE Genetics
MultipleFactors INCLUDE Obesity
VariabilityInSystemicChemotherapyDrugConcentration IS High
VariabilityInSystemicChemotherapyDrugConcentration IS_MORE_THAN Ten-foldForManyDrugs
TwoPeople RECEIVE SameDoseOfGivenDrugBasedOnBsa
ConcentrationOfDrugInBloodstreamOfOnePerson MAY_BE 10TimesHigherOrLowerComparedToThatOfOtherPerson
Variability IS_TYPICAL_WITH ManyChemotherapyDrugsDosedByBsa
Variability WAS_DEMONSTRATED_IN StudyOf14CommonChemotherapyDrugs
PharmacokineticVariability RESULT_IN People
People RECEIVE RightDose
RightDose MAY_AIM_TO OptimalTreatmentEffectiveness
RightDose MINIMIZED ToxicSideEffects
People OVERDOSED SomePeople
SomePeople UNDERDOSED Others
Investigators FOUND 85%OfMetastaticColorectalCancerPatients
MetastaticColorectalCancerPatients TREATED_WITH 5-fluorouracil(5-fu)
5-fluorouracil(5-fu) DID_NOT_RECEIVE OptimalTherapeuticDose
5-fluorouracil(5-fu) DOSED_BY BsaStandard
68% UNDERDOSED 5-fluorouracil(5-fu)
17% OVERDOSED 5-fluorouracil(5-fu)
Controversy HAS_BEEN_OVER UseOfBsa
UseOfBsa CALCULATE ChemotherapyDoses
ChemotherapyDoses FOR PeopleWhoAreObese
PeopleWhoAreObese HAVE HigherBsa
Clinicians OFTEN_REDUCE Dose
Dose CALCULATE BsaFormula
Clinicians REDUCE Dose
Fear HAS_BEEN_OVER Overdosing
This CAN_RESULT_IN Sub-optimalTreatment
ClinicalStudies HAVE_DEMONSTRATED ChemotherapyDosing
ChemotherapyDosing MAY_AIM_TO OptimalSystemicDrugExposure
OptimalSystemicDrugExposure IMPROVED TreatmentOutcomes
OptimalSystemicDrugExposure MINIMIZED ToxicSideEffects
People DOSE_WAS_ADJUSTED_TO_ACHIEVE Pre-determinedTargetExposure
People DOSE_WAS_ADJUSTED_TO_ACHIEVE 84%ImprovementInTreatmentResponseRate
People DOSE_WAS_ADJUSTED_TO_ACHIEVE Six-monthImprovementInOverallSurvival
Dose DOSE_WAS_ADJUSTED_TO_ACHIEVE Pre-determinedTargetExposure
Dose DOSED_BY Bsa
Investigators COMPARED Incidence
Investigators COMPARED Toxicities
Toxicities COMPARED Dose-adjustedPeople
Toxicities BETWEEN PeopleDosedPerBsa
Incidence OF Diarrhea
Diarrhea REDUCED_FROM 18%
Diarrhea REDUCED_TO 4%
Incidence OF HematologicSideEffects
Dose-adjustedPatients WERE_ABLE_TO_BE_TREATED_FOR LongerPeriodsOfTime
Bsa-dosedPeople WERE_TREATED_FOR_A_TOTAL_OF 680Months
PeopleInTheDose-adjustedGroup WERE_TREATED_FOR_A_TOTAL_OF 791Months
CompletingTheCourseOfTreatment IS ImportantFactor
ImportantFactor IN_ACHIEVING BetterTreatmentOutcomes
Results WERE_FOUND_IN Study
Study REDUCED_TO PeopleWithColorectalCancer
PeopleWithColorectalCancer HAVE_BEEN_TREATED_WITH FolfoxRegimen
IncidenceOfSeriousDiarrhea REDUCED_FROM 12%InBsa-dosedGroupOfPatients
IncidenceOfSeriousDiarrhea WAS_REDUCED_TO 1.7%InDose-adjustedGroup
IncidenceOfSevereMucositis WAS_REDUCED_TO 15%
IncidenceOfSevereMucositis WAS_REDUCED_TO 0.8%
FolfoxStudy HAVE_DEMONSTRATED ImprovementInTreatmentOutcomes
PositiveResponse INCREASED_FROM 46%InBsa-dosedGroup
PositiveResponse INCREASED_FROM 70%InDose-adjustedGroup
MedianProgressionFreeSurvival INCREASED_FROM SixMonthsInDoseAdjustedGroup
OverallSurvival IMPROVED_BY SixMonthsInDoseAdjustedGroup
Clinicians INDIVIDUALIZE ChemotherapyDosing
Clinicians CALCULATE DrugLevels
DrugLevels IN BloodPlasma
DrugLevels INDIVIDUALIZE Dose
Dose ACCORDING_TO FormulaOrAlgorithm
FormulaOrAlgorithm MAY_AIM_TO OptimalExposure
EstablishedTargetExposure FOR OptimizedTreatmentEffectiveness
EstablishedTargetExposure MINIMIZED Toxicities
Dosing INDIVIDUALIZE TargetExposure
Dosing INDIVIDUALIZE OptimalResults
Algorithm USED_IN ClinicalTrials
ClinicalTrials RESULTED_IN ImprovedTreatmentOutcomes
Oncologists INDIVIDUALIZING_DOSING_OF SomeCancerDrugs
SomeCancerDrugs INDIVIDUALIZING_DOSING_OF Exposure
Carboplatin RELY_UPON ResultsFromBloodTests
ResultsFromBloodTests CALCULATE OptimalDose
OptimalDose FOR EachPerson
BusulfanDosing RELY_UPON ResultsFromBloodTests
ResultsFromBloodTests CALCULATE OptimalDose
OptimalDose FOR EachPerson
BloodTests AVAILABLE_FOR DoseOptimization
DoseOptimization OF Methotrexate
DoseOptimization OF 5-fu
DoseOptimization OF Paclitaxel
DoseOptimization OF Docetaxel
SerumAlbuminLevel PRIOR_TO ChemotherapyAdministration
SerumAlbuminLevel INDEPENDENT_PROGNOSTIC_PREDICTOR_OF Survival
SerumAlbuminLevel IN VariousCancerTypes
AlkylatingAgents ARE OldestGroupOfChemotherapeutics
AlkylatingAgents ORIGINALLY_DERIVED_FROM MustardGas
MustardGas USED_IN WorldWarI
AlkylatingAgents NOW_MANY_TYPES_OF InUse
AlkylatingAgents REFERRED_TO_AS BecauseOfAbilityToAlkylateMolecules
AbilityToAlkylateMolecules INVOLVES Proteins
AbilityToAlkylateMolecules INVOLVES Rna
AbilityToAlkylateMolecules INVOLVES Dna
AbilityToBindCovalentlyToDna VIA AlkylGroup
AbilityToBindCovalentlyToDna PRIMARY_CAUSE_FOR Anti-cancerEffects
Dna MADE_OF TwoStrands
Molecules MAY_BIND_TWICE_TO OneStrandOfDna
Molecules MAY_BIND_ONCE_TO BothStrandsOfDna
Cell TRIES_TO_REPLICATE_CROSSLINKED_DNA_DURING CellDivision
Cell TRIES_TO_REPAIR_CROSSLINKED_DNA_DURING CellDivision
Break LEADS_TO ProgrammedCellDeath
ProgrammedCellDeath CALLED Apoptosis
AlkylatingAgents WORK_AT AnyPointInCellCycle
AlkylatingAgents KNOWN_AS CellCycle-independentDrugs
FractionOfCellsThatDie DIRECTLY_PROPORTIONAL_TO DoseOfDrug
SubtypesOfAlkylatingAgents ARE NitrogenMustards
SubtypesOfAlkylatingAgents ARE Nitrosoureas
SubtypesOfAlkylatingAgents ARE Tetrazines
SubtypesOfAlkylatingAgents ARE Aziridines
SubtypesOfAlkylatingAgents ARE CisplatinsAndDerivatives
SubtypesOfAlkylatingAgents ARE Non-classicalAlkylatingAgents
NitrogenMustards INCLUDE Mechlorethamine
NitrogenMustards INCLUDE Cyclophosphamide
NitrogenMustards INCLUDE Melphalan
NitrogenMustards INCLUDE Chlorambucil
NitrogenMustards INCLUDE Ifosfamide
NitrogenMustards INCLUDE Busulfan
Nitrosoureas INCLUDE N-nitroso-n-methylurea(mnu)
Nitrosoureas INCLUDE Carmustine(bcnu)
Nitrosoureas INCLUDE Lomustine(ccnu)
Nitrosoureas INCLUDE Semustine(meccnu)
Nitrosoureas INCLUDE Fotemustine
Nitrosoureas INCLUDE Streptozotocin
Tetrazines INCLUDE Dacarbazine
Tetrazines INCLUDE Mitozolomide
Tetrazines INCLUDE Temozolomide
Aziridines INCLUDE Thiotepa
Aziridines INCLUDE Mytomycin
Aziridines INCLUDE Diaziquone(azq)
CisplatinAndDerivatives INCLUDE Cisplatin
CisplatinAndDerivatives INCLUDE Carboplatin
CisplatinAndDerivatives INCLUDE Oxaliplatin
They IMPAIR CellFunction
They IMPAIR CovalentBonds
CovalentBonds IMPAIR AminoGroups
Anti-metabolites BLOCK DnaAndRnaSynthesis
ManyOfThem HAVE SimilarStructure
BuildingBlocks ARE Nucleotides
Nucleotides COMPRISING Nucleobase,Sugar,PhosphateGroup
Nucleobases DIVIDED_INTO PurinesAndPyrimidines
Purines INCLUDE Guanine,Adenine
Pyrimidines INCLUDE Cytosine,Thymine,Uracil
Anti-metabolites RESEMBLE NucleobasesOrNucleosides
Nucleosides ARE NucleotideWithoutPhosphateGroup
Drugs EXERT Effect
Effect BY_BLOCKING EnzymesRequiredForDnaSynthesis
Effect BY_BECOMING_INCORPORATED_INTO DnaOrRna
Dna BLOCK Itself
Misincorporation OF_MOLECULES_INTO Dna
Anti-metabolites ARE CellCycleDependent
They WORK_DURING SpecificPartOfCellCycle
SpecificPartOfCellCycle IS S-phase
Proportionally NO_MORE_CELL_DEATH_OCCURS_WITH IncreasedDoses
SubtypesOfAnti-metabolites ARE Anti-folates,Fluoropyrimidines,DeoxynucleosideAnalogues,Thiopurines
Anti-folates INCLUDE Methotrexate
Anti-folates INCLUDE Pemetrexed
Methotrexate INHIBITS DihydrofolateReductase
DihydrofolateReductase REGENERATES Tetrahydrofolate
Methotrexate ARE_AFFECTED_BY Enzyme
Enzyme IS Dhfr
Dhfr ARE_AFFECTED_BY CellularLevelsOfFolateCoenzymes
FolateCoenzymes REQUIRED_FOR ThymidylateProduction
FolateCoenzymes REQUIRED_FOR PurineProduction
Thymidylate ESSENTIAL_FOR DnaSynthesis
Purine ESSENTIAL_FOR DnaSynthesis
Purine ESSENTIAL_FOR CellDivision
Pemetrexed AFFECTS PurineProduction
Pemetrexed AFFECTS PyrimidineProduction
Pemetrexed INHIBITS DnaSynthesis
Pemetrexed PRIMARILY_INHIBITS ThymidylateSynthase
Pemetrexed ARE_AFFECTED_BY Dhfr
Pemetrexed ARE_AFFECTED_BY AminoimidazoleCarboxamideRibonucleotideFormyltransferase
Pemetrexed HAS_EFFECTS_ON GlycinamideRibonucleotideFormyltransferase
Fluoropyrimidines INCLUDE Fluorouracil
Fluoropyrimidines INCLUDE Capecitabine
Fluorouracil IS NucleobaseAnalogue
Fluorouracil METABOLISED_IN Cells
Fluorouracil FORMS ActiveProducts
ActiveProducts INCLUDE 5-fluourouridineMonophosphate
5-fluourouridineMonophosphate INCORPORATED_INTO Rna
Anti-microtubuleAgents ARE Drugs
Anti-microtubuleAgents ARE Plant-derivedChemicals
Plant-derivedChemicals BLOCK CellDivision
Plant-derivedChemicals PREVENT MicrotubuleFunction
Microtubules CONSTITUTE TwoProteins
Microtubules ARE ImportantCellularStructure
Microtubules REQUIRED_FOR CellDivision
Microtubules REQUIRED_FOR OtherCellularFunctions
DynamicStructures PERMANENTLY_IN StateOfAssembly
DynamicStructures PERMANENTLY_IN StateOfDisassembly
VincaAlkaloids ARE MainGroupsOfAnti-microtubuleAgents
Taxanes ARE MainGroupsOfAnti-microtubuleAgents
BothOfTheseGroupsOfDrugs PRIMARY_CAUSE_FOR MicrotubuleDysfunction
VincaAlkaloids PREVENT AssemblyOfMicrotubules
Taxanes PREVENT DisassemblyOfMicrotubules
They PRIMARY_CAUSE_FOR MitoticCatastropheInTheCancerCells
Occurs PRIMARY_CAUSE_FOR ProgrammedCellDeath
ProgrammedCellDeath IS Apoptosis
Drugs AFFECT BloodVesselGrowth
Tumours UTILISE BloodVesselGrowth
Tumours UTILISE Grow
Tumours UTILISE Metastasise
VincaAlkaloids REFERRED_TO_AS MadagascarPeriwinkle
MadagascarPeriwinkle REFERRED_TO_AS VincaRosea
VincaAlkaloids BLOCK SpecificSitesOnTubulin
VincaAlkaloids BLOCK AssemblyOfTubulinIntoMicrotubules
VincaAlkaloids ARE NaturalProducts
NaturalProducts INCLUDE Vincristine
NaturalProducts INCLUDE Vinblastine
Semi-syntheticVincaAlkaloids WERE_PRODUCED Vinorelbine
Vinorelbine USED_IN TreatmentOfNon-small-cellLungCancer
Semi-syntheticVincaAlkaloids WERE_PRODUCED Vindesine
Semi-syntheticVincaAlkaloids WERE_PRODUCED Vinflunine
Drugs ARE CellCycle-specific
Drugs BLOCK TubulinMoleculesInS-phase
Drugs PREVENT ProperMicrotubuleFormationRequiredForM-phase
Taxanes ARE NaturalAndSemi-syntheticDrugs
Paclitaxel ORIGINALLY_DERIVED_IN TaxusBrevifolia
TaxusBrevifolia IS ThePacificYew
Docetaxel ARE_PRODUCED_SEMI-SYNTHETICALLY_FROM AChemicalFoundInTheBarkOfAnotherYewTree
AChemical ARE_PRODUCED_SEMI-SYNTHETICALLY_FROM TheBarkOfAnotherYewTree
AnotherYewTree IS TaxusBaccata
Podophyllotoxin ASSOCIATED_WITH AntineoplasticLignan
Podophyllotoxin FROM AmericanMayapple
Podophyllotoxin FROM HimalayanMayapple
Podophyllotoxin ASSOCIATED_WITH Anti-microtubuleActivity
Anti-microtubuleActivity IS Mechanism
Mechanism ASSOCIATED_WITH VincaAlkaloids
VincaAlkaloids ASSOCIATED_WITH Tubulin
VincaAlkaloids INHIBITING MicrotubuleFormation
Podophyllotoxin USED_TO_PRODUCE Etoposide
Podophyllotoxin USED_TO_PRODUCE Teniposide
TopoisomeraseInhibitors ARE Drugs
TopoisomeraseInhibitors ARE Drugs
Drugs AFFECT ActivityOfTwoEnzymes
DnaDouble-strandHelix DURING DnaReplication
DnaDouble-strandHelix DURING Transcription
Stress CAUSED_BY Effect
Effect IS_IN_PART_AIDED_BY TopoisomeraseEnzymes
TopoisomeraseEnzymes PRODUCE Single-strandBreaks
TopoisomeraseEnzymes PRODUCE Double-strandBreaks
Single-strandBreaks INTO Dna
Double-strandBreaks INTO Dna
Reducing TENSION_IN DnaStrand
ReducingTensionInDnaStrand ALLOWS NormalUnwindingOfDna
NormalUnwindingOfDna ALLOWS Replication
NormalUnwindingOfDna ALLOWS Transcription
InhibitionOfTopoisomeraseI INTERFERES_WITH Processes
InhibitionOfTopoisomeraseIi INTERFERES_WITH Processes
TwoTopoisomeraseIInhibitors FROM Camptothecin
Camptothecin FROM ChineseOrnamentalTreeCamptothecaAcuminata
Drugs LEADS_TO TopoisomeraseIi
TopoisomeraseIiPoisons LEADS_TO IncreasedLevelsEnzymesBoundToDna
IncreasedLevelsEnzymesBoundToDna LEADS_TO DnaReplication
IncreasedLevelsEnzymesBoundToDna PREVENTS Transcription
IncreasedLevelsEnzymesBoundToDna LEADS_TO DnaStrandBreaks
DnaStrandBreaks LEADS_TO ProgrammedCellDeath
ProgrammedCellDeath IS Apoptosis
TopoisomeraseIiPoisons INCLUDE Etoposide
TopoisomeraseIiPoisons INCLUDE Doxorubicin
TopoisomeraseIiPoisons INCLUDE Mitoxantrone
TopoisomeraseIiPoisons INCLUDE Teniposide
CatalyticInhibitors ARE Drugs
CatalyticInhibitors BLOCK ActivityOfTopoisomeraseIi
ActivityOfTopoisomeraseIi PREVENT DnaSynthesis
ActivityOfTopoisomeraseIi PREVENT Translation
Dna CANNOT_UNWIND_PROPERLY_BECAUSE_OF ActivityOfTopoisomeraseIi
CatalyticInhibitors INCLUDE Novobiocin
CatalyticInhibitors INCLUDE Merbarone
CatalyticInhibitors INCLUDE Aclarubicin
Novobiocin HAVE OtherSignificantMechanismsOfAction
Merbarone HAVE OtherSignificantMechanismsOfAction
Aclarubicin HAVE OtherSignificantMechanismsOfAction
CytotoxicAntibiotics ARE VariedGroupOfDrugs
VariedGroupOfDrugs HAVE VariousMechanismsOfAction
VariedGroupOfDrugs HAVE ChemotherapyIndication
ChemotherapyIndication IS InterruptCellDivision
Anthracyclines ARE MostImportantSubgroup
Anthracyclines INCLUDE Bleomycins
OtherProminentExamples INCLUDE MitomycinC
OtherProminentExamples INCLUDE Actinomycin
Anthracyclines INCLUDE Doxorubicin
Anthracyclines INCLUDE Daunorubicin
Doxorubicin FROM BacteriumStreptomycesPeucetius
Daunorubicin FROM BacteriumStreptomycesPeucetius
Compounds INCLUDE Epirubicin
Compounds INCLUDE Idarubicin
Drugs IN AnthracyclineGroup
AnthracyclineGroup INCLUDE Pirarubicin
AnthracyclineGroup INCLUDE Aclarubicin
AnthracyclineGroup INCLUDE Mitoxantrone
Mechanisms OF Anthracyclines
Anthracyclines INCLUDE DnaIntercalation
DnaIntercalation DAMAGE Dna
Anthracyclines INCLUDE GenerationOfHighlyReactiveFreeRadicals
GenerationOfHighlyReactiveFreeRadicals DAMAGE IntercellularMolecules
Anthracyclines INCLUDE TopoisomeraseInhibition
Actinomycin IS ComplexMolecule
ComplexMolecule INHIBITING Dna
Dna PREVENTS RnaSynthesis
Bleomycin FROM StreptomycesVerticillus
Bleomycin INTERCALATES Dna
Bleomycin INDUCE FreeRadicals
FreeRadicals DAMAGE Dna
Bleomycin BINDS_TO MetalIon
Bleomycin LEADS_TO ChemicallyReduced
Bleomycin REACTS_WITH Oxygen
Mitomycin IS_TYPICAL_WITH CytotoxicAntibiotic
CytotoxicAntibiotic WITH_THE_ABILITY_TO AlkylateDna
MostChemotherapy IS_DELIVERED Intravenously
ANumberOfAgents CAN_BE_ADMINISTERED Orally
ANumberOfAgents E.G. Melphalan
ANumberOfAgents E.G. Busulfan
ANumberOfAgents E.G. Capecitabine
OralTherapies PRESENT AdditionalChallenges
OralTherapies FOR Patients
OralTherapies FOR CareTeams
Patients MAINTAIN AdherenceToTreatmentPlans
Patients SUPPORT AdherenceToTreatmentPlans
CareTeams MAINTAIN AdherenceToTreatmentPlans
CareTeams SUPPORT AdherenceToTreatmentPlans
IntravenousMethods OF DrugDelivery
IntravenousMethods KNOWN_AS VascularAccessDevices
VascularAccessDevices INCLUDE WingedInfusionDevice
VascularAccessDevices INCLUDE PeripheralVenousCatheter
VascularAccessDevices INCLUDE MidlineCatheter
VascularAccessDevices INCLUDE PeripherallyInsertedCentralCatheter(picc)
VascularAccessDevices INCLUDE CentralVenousCatheter
VascularAccessDevices INCLUDE ImplantablePort
Devices HAVE DifferentApplications
Applications REGARDING DurationOfChemotherapyTreatment
Applications REGARDING MethodOfDelivery
Applications REGARDING TypesOfChemotherapeuticAgent
DependingOnThePerson THE_CANCER TheStageOfCancer
DependingOnThePerson THE_TYPE_OF_CHEMOTHERAPY IntravenousChemotherapy
DependingOnThePerson THE_DOSAGE IntravenousChemotherapy
IntravenousChemotherapy MAY_BE_GIVEN_ON InpatientBasis
IntravenousChemotherapy MAY_BE_GIVEN_ON OutpatientBasis
IntravenousChemotherapy ADMINISTRATION Continuous
IntravenousChemotherapy ADMINISTRATION Frequent
IntravenousChemotherapy ADMINISTRATION Prolonged
VariousSystems MAY_BE_SURGICALLY_INSERTED_INTO Vasculature
Systems MAINTAIN_ACCESS Vasculature
Systems HAVE LowerInfectionRisk
Systems ARE_MUCH_LESS_PRONE_TO Phlebitis
Systems ARE_MUCH_LESS_PRONE_TO Extravasation
Systems ELIMINATE Need
Systems ELIMINATE RepeatedInsertion
Systems ELIMINATE PeripheralCannulae
Systems ARE HickmanLine
Systems ARE Port-a-cath
Systems ARE PiccLine
IsolatedLimbPerfusion FOR Melanoma
IsolatedLimbPerfusion FOR SomeTumors
IsolatedInfusionOfChemotherapy INTO Liver
IsolatedInfusionOfChemotherapy INTO Lung
Approaches FOR VeryHighDoseOfChemotherapy
Approaches FOR ChemotherapyToTumorSites
Approaches CAUSE OverwhelmingSystemicDamage
Approaches FOR SolitaryOrLimitedMetastases
Approaches ARE_BY_DEFINITION NotSystemic
Approaches FOR DistributedMetastases
Approaches FOR Micrometastases
TopicalChemotherapies FOR SomeCasesOfNon-melanomaSkinCancer
TopicalChemotherapies E.G. 5-fluorouracil
Cancer HAS CentralNervousSystemInvolvement
Cancer HAS MeningealDisease
IntrathecalChemotherapy MAY_BE_ADMINISTERED Cancer
ChemotherapeuticTechniques HAVE RangeOfSideEffects
RangeOfSideEffects ARE_AFFECTED_BY TypeOfMedicationsUsed
TypeOfMedicationsUsed AFFECT Fast-dividingCellsOfBody
Fast-dividingCellsOfBody INCLUDE BloodCells
Fast-dividingCellsOfBody INCLUDE CellsLiningMouth
Fast-dividingCellsOfBody INCLUDE CellsLiningStomach
Fast-dividingCellsOfBody INCLUDE CellsLiningIntestines
Chemotherapy-relatedToxicities CAN_RESULT_IN Administration
Chemotherapy-relatedToxicities CAN_RESULT_IN Hours
Chemotherapy-relatedToxicities CAN_RESULT_IN Days
Chemotherapy-relatedToxicities CAN_RESULT_IN Weeks
Chemotherapy-relatedToxicities CAN_RESULT_IN Years
Immunosuppression AND Myelosuppression
ChemotherapeuticRegimens CAN_RESULT_IN DepressionOfTheImmuneSystem
ChemotherapeuticRegimens IMPAIR BoneMarrow
BoneMarrow RESULT_IN DecreaseOfWhiteBloodCells
BoneMarrow RESULT_IN DecreaseOfRedBloodCells
BoneMarrow RESULT_IN DecreaseOfPlatelets
Anemia MAY_REQUIRE BloodTransfusion
Thrombocytopenia MAY_REQUIRE BloodTransfusion
Neutropenia IMPROVED_BY SyntheticG-csf
Neutropenia DECREASE_OF NeutrophilGranulocyteCount
NeutrophilGranulocyteCount DECREASE_OF 0.5X10^9/litre
SyntheticG-csf E.G. Filgrastim
SyntheticG-csf E.G. Lenograstim
SyntheticG-csf E.G. EfbemalenograstimAlfa
Myelosuppression OCCURS_IN SomeRegimens
Myelosuppression VERY_SEVERE AlmostAllBoneMarrowStemCells
BoneMarrowStemCells PRODUCE WhiteAndRedBloodCells
AlmostAllBoneMarrowStemCells DESTROYED AllogenicOrAutologousBoneMarrowCellTransplants
AutologousBmts CELLS_REMOVED_FROM PersonBeforeTreatment
Cells CELLS_REMOVED_FROM Afterward
AllogenicBmts CELLS_REMOVED_FROM Donor
SomePeople DEVELOP Diseases
Interference WITH BoneMarrow
PeopleReceivingChemotherapy ARE_ENCOURAGED_TO_WASH Hands
PeopleReceivingChemotherapy ARE_ENCOURAGED_TO_AVOID SickPeople
PeopleReceivingChemotherapy ARE_ENCOURAGED_TO_TAKE Infection-reducingSteps
85%OfInfections ARE_DUE_TO NaturallyOccurringMicroorganisms
NaturallyOccurringMicroorganisms ARE_IN Person'sOwnGastrointestinalTract
NaturallyOccurringMicroorganisms ARE_IN Skin
Infections MAY_MANIFEST_AS SystemicInfections
Infections MAY_MANIFEST_AS LocalizedOutbreaks
SystemicInfections E.G. Sepsis
LocalizedOutbreaks E.G. HerpesSimplex
LocalizedOutbreaks E.G. Shingles
LocalizedOutbreaks E.G. OtherMembersOfTheHerpesviridea
RiskOfIllnessAndDeath MINIMIZED CommonAntibiotics
CommonAntibiotics E.G. Quinolones
CommonAntibiotics E.G. Trimethoprim/sulfamethoxazole
Quinolones MINIMIZED HematologicalCancer
ChemotherapyTreatments ARE_POSTPONED_BECAUSE ImmuneSystemIsSuppressedToACriticallyLowLevel
Japan IN Government
Government HAS_APPROVED UseOfMedicinalMushrooms
MedicinalMushrooms LIKE TrametesVersicolor
TrametesVersicolor COUNTERACT DepressionOfImmuneSystem
People UNDERGOING Chemotherapy
Trilaciclib MINIMIZED Cyclin-dependentKinase4/6
Trilaciclib FOR PreventionOfMyelosuppressionCausedByChemotherapy
Drug PRIOR_TO Chemotherapy
Drug MINIMIZED BoneMarrowFunction
ImmuneSystemSuppression PRIMARY_CAUSE_FOR NeutropenicEnterocolitis
NeutropenicEnterocolitis IS Life-threateningGastrointestinalComplicationOfChemotherapy
NeutropenicEnterocolitis IS Typhlitis
Typhlitis IS IntestinalInfection
IntestinalInfection MAY_MANIFEST_AS Symptoms
Symptoms INCLUDE Nausea
Symptoms INCLUDE Vomiting
Symptoms INCLUDE Diarrhea
Symptoms INCLUDE DistendedAbdomen
Symptoms INCLUDE Fever
Symptoms INCLUDE Chills
Symptoms INCLUDE AbdominalPain
Symptoms INCLUDE Tenderness
Typhlitis IS_A MedicalEmergency
Typhlitis HAS PoorPrognosis
Typhlitis IS_OFTEN_FATAL_UNLESS PromptlyRecognizedAndAggressivelyTreated
SuccessfulTreatment HINGES_ON EarlyDiagnosis
EarlyDiagnosis HINGES_ON HighIndexOfSuspicion
EarlyDiagnosis HINGES_ON UseOfCtScanning
NonoperativeTreatment FOR UncomplicatedCases
ElectiveRightHemicolectomy TO_PREVENT Recurrence
GastrointestinalDistress IS_A_TYPE_OF Symptom
Nausea CAN_RESULT_IN ChemotherapeuticMedications
Vomiting CAN_RESULT_IN ChemotherapeuticMedications
Anorexia CAN_RESULT_IN ChemotherapeuticMedications
Diarrhea CAN_RESULT_IN ChemotherapeuticMedications
AbdominalCramps CAN_RESULT_IN ChemotherapeuticMedications
Constipation CAN_RESULT_IN ChemotherapeuticMedications
ChemotherapeuticMedications DESTROYED Fast-dividingCells
Malnutrition CAN_RESULT_IN RecipientDoesNotEatOrDrinkEnough
Malnutrition CAN_RESULT_IN PersonVomitsFrequently
Malnutrition CAN_RESULT_IN PersonVomitsFrequently
Malnutrition CAN_RESULT_IN GastrointestinalDamage
Result CAN_RESULT_IN RapidWeightLoss
Result CAN_RESULT_IN WeightGain
Result CAN_RESULT_IN WeightGain
Result CAN_RESULT_IN PersonEatsTooMuchInAnEffortToAllayNauseaOrHeartburn
WeightGain ALSO_CAUSES SomeSteroidMedications
Side-effects CAN_FREQUENTLY_BE_REDUCED_OR_ELIMINATED_WITH AntiemeticDrugs
Low-certaintyEvidence ALSO_SUGGESTS_THAT ProbioticsMayHaveAPreventativeAndTreatmentEffectOfDiarrhoeaRelatedToChemotherapyAloneAndWithRadiotherapy
Diarrhoea RELATED_TO Chemotherapy
Diarrhoea RELATED_TO Radiotherapy
IndexOfSuspicion IS_APPROPRIATE_SINCE DiarrhoeaAndBloatingAreAlsoSymptomsOfTyphlitis
Typhlitis REQUIRES ImmediateTreatment
Anemia CAN_BE_A_COMBINED_OUTCOME_CAUSED_BY MyelosuppressiveChemotherapy
Anemia CAN_BE_A_COMBINED_OUTCOME_CAUSED_BY PossibleCancer-relatedCauses
PossibleCancer-relatedCauses CAN_RESULT_IN Bleeding
PossibleCancer-relatedCauses SUCH_AS BloodCellDestruction
PossibleCancer-relatedCauses SUCH_AS HereditaryDisease
PossibleCancer-relatedCauses SUCH_AS KidneyDysfunction
PossibleCancer-relatedCauses SUCH_AS NutritionalDeficiencies
PossibleCancer-relatedCauses SUCH_AS AnemiaOfChronicDisease
Treatments CAN_FREQUENTLY_BE_REDUCED_OR_ELIMINATED_WITH Anemia
Treatments CAN_FREQUENTLY_BE_REDUCED_OR_ELIMINATED_WITH IncludeHormonesToBoostBloodProduction
Treatments TO_MITIGATE IronSupplements
Treatments TO_MITIGATE BloodTransfusions
MyelosuppressiveTherapy CAN_RESULT_IN ATendencyToBleedEasily
ATendencyToBleedEasily CAN_RESULT_IN Anemia
Medications THAT_KILL RapidlyDividingCells
Medications THAT_KILL BloodCells
Medications THAT_KILL ReduceTheNumberOfPlateletsInTheBlood
ReduceTheNumberOfPlateletsInTheBlood RESULT_IN Bruises
ReduceTheNumberOfPlateletsInTheBlood RESULT_IN Bleeding
ExtremelyLowPlateletCounts MAY_BE_TEMPORARILY_BOOSTED_THROUGH PlateletTransfusions
NewDrugs TO_INCREASE PlateletCountsDuringChemotherapyAreBeingDeveloped
ChemotherapyTreatments ARE_POSTPONED_TO_ALLOW PlateletCountsToRecover
Fatigue RESULT_FROM Cancer
Fatigue MAY_BE_A_CONSEQUENCE_OF Treatment
Fatigue CAN_LAST_FOR Months
Fatigue CAN_LAST_FOR Years
Anemia IS PhysiologicalCauseOfFatigue
Anemia RESULT_FROM Chemotherapy
Anemia RESULT_FROM Surgery
Anemia RESULT_FROM Radiotherapy
Anemia CAN_BE_CAUSED_BY PrimaryDisease
Anemia CAN_BE_CAUSED_BY MetastaticDisease
Anemia CAN_BE_CAUSED_BY NutritionalDepletion
AerobicExercise HAS_BEEN_FOUND_TO_BE_BENEFICIAL_IN ReducingFatigue
AerobicExercise HAS_BEEN_FOUND_TO_BE_BENEFICIAL_IN People
People HAVE SolidTumours
Nausea AND Vomiting
Nausea ARE Side-effects
Nausea RELATED_TO CancerTreatment
Nausea COMMON_WITH Treatments
Nausea COMMON_WITH FormsOfCancer
Vomiting ARE Side-effects
Vomiting RELATED_TO CancerTreatment
Vomiting COMMON_WITH Treatments
Vomiting COMMON_WITH FormsOfCancer
CoatesEtAl. FOUND PeopleReceivingChemotherapy
PeopleReceivingChemotherapy RESULTED_IN Nausea
Nausea RESULTED_IN FirstMostSevereSide-effects
PeopleReceivingChemotherapy RESULTED_IN Vomiting
Vomiting RESULTED_IN SecondMostSevereSide-effects
PeopleReceivingHighlyEmetogenicAgents RESULTED_IN PotentiallyCurativeTreatments
PeopleReceivingHighlyEmetogenicAgents RESULTED_IN PotentiallyCurativeTreatments
Chemotherapy-inducedNauseaAndVomiting ARE CommonWithManyTreatments
Chemotherapy-inducedNauseaAndVomiting ARE CommonWithSomeFormsOfCancer
NovelClassesOfAntiemetics RESULTED_IN SinceThe1990s
NovelClassesOfAntiemetics RESULTED_IN SinceThe1990s
NovelClassesOfAntiemetics RESULTED_IN StandardInChemotherapyRegimens
NovelClassesOfAntiemetics IMPROVED ManageSymptoms
Mediation RESULTED_IN IncreasedQualityOfLife
Mediation RESULTED_IN MoreEfficientTreatmentCycles
Mediation RESULTED_IN LessStoppageOfTreatment
Mediation RESULTED_IN BetterTolerance
Mediation RESULTED_IN BetterOverallHealth
HairLoss CAN_BE_CAUSED_BY Chemotherapy
Chemotherapy INDUCE RapidlyDividingCells
OtherMedications CAN_RESULT_IN HairToThin
Effects ARE Temporary
Hair USUALLY_STARTS_TO_REGROW AFewWeeksAfterTheLastTreatment
Hair SOMETIMES HasATendencyToCurlAfterRegrowth
Hair RESULTS_IN ChemoCurls
SevereHairLoss CAUSE DrugsSuchAsDoxorubicin,Daunorubicin,Paclitaxel,Docetaxel,Cyclophosphamide,IfosfamideAndEtoposide
PermanentThinningOrHairLoss INDUCE SomeStandardChemotherapyRegimens
Chemotherapy INDUCED HairLoss
HairLoss INDUCED Non-androgenicMechanism
HairLoss CAN_MANIFEST_AS AlopeciaTotalis
HairLoss CAN_MANIFEST_AS TelogenEffluvium
HairLoss CAN_MANIFEST_AS AlopeciaAreata
HairLoss INDUCED SystemicTreatment
SystemicTreatment CAN_RESULT_IN HighMitoticRateOfHairFollicles
HairLoss MORE_REVERSIBLE_THAN AndrogenicHairLoss
AndrogenicHairLoss ALTHOUGH PermanentCasesCanOccur
Chemotherapy INDUCED HairLossInWomen
HairLossInWomen MORE_OFTEN_THAN Men
ScalpCooling CAN_BE_THOUGHT_OF_AS Means
Means INHIBITING PermanentHairLoss
Means INHIBITING TemporaryHairLoss
Concerns RAISED_ABOUT Method
DevelopmentOfSecondaryNeoplasia AFTER SuccessfulChemotherapyOrRadiotherapyTreatment
SecondaryNeoplasia CAN_OCCUR Development
MostCommonSecondaryNeoplasm IS SecondaryAcuteMyeloidLeukemia
SecondaryAcuteMyeloidLeukemia PRIMARY_CAUSE_FOR TreatmentWithAlkylatingAgentsOrTopoisomeraseInhibitors
SurvivorsOfChildhoodCancer ARE MoreThan13TimesAsLikelyToGetASecondaryNeoplasmDuringThe30YearsAfterTreatmentThanTheGeneralPopulation
Increase CAN_BE_ATTRIBUTED_TO NotAllOfThisIncrease
Increase CAN_BE_ATTRIBUTED_TO Chemotherapy
SomeTypesOfChemotherapy ARE Gonadotoxic
SomeTypesOfChemotherapy CAN_BE_ATTRIBUTED_TO Infertility
ChemotherapiesWithHighRisk INCLUDE Procarbazine
ChemotherapiesWithHighRisk INCLUDE AlkylatingDrugs
AlkylatingDrugs SUCH_AS Cyclophosphamide
AlkylatingDrugs SUCH_AS Ifosfamide
AlkylatingDrugs SUCH_AS Busulfan
AlkylatingDrugs SUCH_AS Melphalan
AlkylatingDrugs SUCH_AS Chlorambucil
AlkylatingDrugs SUCH_AS Chlormethine
DrugsWithMediumRisk INCLUDE Doxorubicin
DrugsWithMediumRisk INCLUDE PlatinumAnalogs
PlatinumAnalogs SUCH_AS Cisplatin
PlatinumAnalogs SUCH_AS Carboplatin
TherapiesWithLowRiskOfGonadotoxicity INCLUDE PlantDerivatives
PlantDerivatives SUCH_AS Vincristine
PlantDerivatives SUCH_AS Vinblastine
TherapiesWithLowRiskOfGonadotoxicity INCLUDE Antibiotics
Antibiotics SUCH_AS Bleomycin
Antibiotics SUCH_AS Dactinomycin
TherapiesWithLowRiskOfGonadotoxicity INCLUDE Antimetabolites
Antimetabolites SUCH_AS Methotrexate
Antimetabolites SUCH_AS Mercaptopurine
Antimetabolites SUCH_AS 5-fluorouracil
FemaleInfertility BY Chemotherapy
Chemotherapy APPEARS_TO_BE SecondaryToPrematureOvarianFailure
PrematureOvarianFailure BY LossOfPrimordialFollicles
LossOfPrimordialFollicles IS NotNecessarilyADirectEffectOfTheChemotherapeuticAgents
LossOfPrimordialFollicles APPEARS_TO_BE IncreasedRateOfGrowthInitiation
IncreasedRateOfGrowthInitiation APPEARS_TO_BE DamagedDevelopingFollicles
People MAY_CHOOSE_BETWEEN SeveralMethodsOfFertilityPreservation
SeveralMethodsOfFertilityPreservation PRIOR_TO Chemotherapy
SeveralMethodsOfFertilityPreservation INCLUDING CryopreservationOfSemen
SeveralMethodsOfFertilityPreservation INCLUDING OvarianTissue
SeveralMethodsOfFertilityPreservation INCLUDING Oocytes
SeveralMethodsOfFertilityPreservation INCLUDING Embryos
MoreThanHalfOfCancerPatients ARE Elderly
ThisAdverseEffect IS_ONLY_RELEVANT_FOR AMinorityOfPatients
AStudyInFranceBetween1999And2011 CAME_TO TheResult
EmbryoFreezingBeforeAdministrationOfGonadotoxicAgentsToFemales PRIMARY_CAUSE_FOR ADelayOfTreatmentIn34%OfCases
EmbryoFreezingBeforeAdministrationOfGonadotoxicAgentsToFemales PRIMARY_CAUSE_FOR ALiveBirthIn27%OfSurvivingCasesWhoWantedToBecomePregnant
TheFollow-upTime VARYING_BETWEEN 1And13Years
ProtectiveOrAttenuatingAgents INCLUDE GnrhAnalogs
SeveralStudies HAVE_SHOWN ProtectiveEffectInVivoInHumans
SomeStudies HAVE_SHOWN NoSuchEffect
Sphingosine-1-phosphate(s1p) HAVE_SHOWN SimilarEffect
Mechanism INHIBITING SphingomyelinApoptoticPathway
SphingomyelinApoptoticPathway INHIBITING ApoptosisActionOfChemotherapyDrugs
Chemotherapy USED_IN ConditioningRegimen
ConditioningRegimen IN HematopoieticStemCellTransplantation
Study OF People
People CONDITIONED_WITH Cyclophosphamide
Cyclophosphamide ALONE_FOR SevereAplasticAnemia
Result THAT OvarianRecoveryOccurred
OvarianRecovery IN AllWomenYoungerThan26Years
OvarianRecovery IN FiveOf16WomenOlderThan26Years
Chemotherapy IS TeratogenicDuringPregnancy
Abortion IS_RECOMMENDED_IF Pregnancy
Pregnancy IS_FOUND_DURING Chemotherapy
Second-AndThird-trimesterExposure DOES_NOT_USUALLY_INCREASE TeratogenicRisk
Second-AndThird-trimesterExposure DOES_NOT_USUALLY_INCREASE AdverseEffectsOnCognitiveDevelopment
Second-AndThird-trimesterExposure MAY_INCREASE RiskOfVariousComplicationsOfPregnancy
Second-AndThird-trimesterExposure MAY_INCREASE RiskOfFetalMyelosuppression
Males TREATED_WITH Chemotherapy
Males HAVE_BEEN_TREATED_WITH Radiotherapy
Males INCREASE_IN GeneticDefects
Males INCREASE_IN CongenitalMalformations
GeneticDefects IN Children
CongenitalMalformations IN Children
Children CONCEIVED_AFTER Therapy
UseOf ASSISTED_REPRODUCTIVE_TECHNOLOGIES Increase
AssistedReproductiveTechnologies INCREASE Risk
AssistedReproductiveTechnologies INCREASE Risk
MicromanipulationTechniques INCREASE Risk
Females UNDERGONE Chemotherapy
Females MISCARRIAGE NotIncreased
Females CONGENITAL_MALFORMATIONS NotIncreased
CongenitalMalformations IN SubsequentConceptions
InVitroFertilization PRACTISED_BETWEEN Treatment
InVitroFertilization PRACTISED_AFTER Treatment
PossibleGeneticRisks TO GrowingOocytes
Babies BE_SCREENED Recommended
People UNDERGOING Chemotherapy
People EXPERIENCE Chemotherapy-inducedPeripheralNeuropathy
Chemotherapy-inducedPeripheralNeuropathy IS ProgressiveCondition
Chemotherapy-inducedPeripheralNeuropathy IS EnduringCondition
Chemotherapy-inducedPeripheralNeuropathy IS IrreversibleCondition
Chemotherapy-inducedPeripheralNeuropathy RESULTS_IN Pain
Chemotherapy-inducedPeripheralNeuropathy RESULTS_IN Tingling
Chemotherapy-inducedPeripheralNeuropathy CAUSING Numbness
Chemotherapy-inducedPeripheralNeuropathy CAUSING SensitivityToCold
Chemotherapy-inducedPeripheralNeuropathy CAUSING Hands
Chemotherapy-inducedPeripheralNeuropathy BEGINNING_IN Feet
Chemotherapy-inducedPeripheralNeuropathy PROGRESSING_TO Arms
Chemotherapy-inducedPeripheralNeuropathy PROGRESSING_TO Legs
ChemotherapyDrugs ASSOCIATED_WITH Cipn
ChemotherapyDrugs INCLUDE Thalidomide
ChemotherapyDrugs INCLUDE Epothilones
ChemotherapyDrugs INCLUDE VincaAlkaloids
ChemotherapyDrugs INCLUDE Taxanes
ChemotherapyDrugs INCLUDE ProteasomeInhibitors
ChemotherapyDrugs INCLUDE Platinum-basedDrugs
Cipn CAUSE DeterminedByChoiceOfDrug
Cipn RESULTS_IN DeterminedByDurationOfUse
Cipn RESULTS_IN DeterminedByTotalAmountConsumed
Cipn CAUSE DeterminedByWhetherPersonAlreadyHasPeripheralNeuropathy
Symptoms ARE MainlySensory
Symptoms ARE AffectedByMotorNerves
Symptoms ARE AffectedByAutonomicNervousSystem
Cipn FOLLOWS FirstChemotherapyDose
Cipn INCREASES_IN_SEVERITY_AS TreatmentContinues
Progression LEVELS_OFF_AT CompletionOfTreatment
Platinum-basedDrugs ARE Exception
Sensation MAY_CONTINUE_TO_DETERIORATE_FOR SeveralMonthsAfterEndOfTreatment
Cipn APPEARS_TO_BE Irreversible
SomePeople RECEIVING Chemotherapy
SomePeople REPORT Fatigue
SomePeople REPORT Non-specificNeurocognitiveProblems
Non-specificNeurocognitiveProblems SUCH_AS InabilityToConcentrate
InabilityToConcentrate REFERRED_TO_AS Post-chemotherapyCognitiveImpairment
Post-chemotherapyCognitiveImpairment REFERRED_TO_AS ChemoBrain
ChemoBrain IN PopularAndSocialMedia
LargeTumors HAVE HighWhiteCellCounts
LargeTumors SUCH_AS Lymphomas
LargeTumors SUCH_AS Teratomas
LargeTumors SUCH_AS SomeLeukemias
SomePeople DEVELOP TumorLysisSyndrome
TumorLysisSyndrome RESULTED_IN RapidBreakdownOfCancerCells
RapidBreakdownOfCancerCells RESULTED_IN ReleaseOfChemicals
ReleaseOfChemicals FROM InsideOfTheCells
HighLevelsOfUricAcid FOUND_IN Blood
HighLevelsOfPotassium FOUND_IN Blood
HighLevelsOfPhosphate FOUND_IN Blood
HighLevelsOfPhosphate INDUCE SecondaryHypoparathyroidism
SecondaryHypoparathyroidism RESULTS_IN LowLevelsOfCalciumInTheBlood
LowLevelsOfCalciumInTheBlood CAUSES KidneyDamage
HighLevelsOfPotassium CAN_CAUSE CardiacArrhythmia
Prophylaxis IS_AVAILABLE_FOR TumorLysisSyndrome
Prophylaxis IS_OFTEN_INITIATED_IN PeopleWithLargeTumors
Side-effect CAN_RESULT_IN Death
Side-effect IS Dangerous
Side-effect IS Untreated
Cardiotoxicity IS EspeciallyProminentWithTheUseOfAnthracyclineDrugs
AnthracyclineDrugs INCLUDE Doxorubicin
AnthracyclineDrugs INCLUDE Epirubicin
AnthracyclineDrugs INCLUDE Idarubicin
AnthracyclineDrugs INCLUDE LiposomalDoxorubicin
Cause IS MostLikelyDueToTheProductionOfFreeRadicalsInTheCell
ProductionOfFreeRadicals RESULTS_IN DnaDamage
ChemotherapeuticAgents CAUSE Cardiotoxicity
ChemotherapeuticAgents INCLUDE Cyclophosphamide
ChemotherapeuticAgents INCLUDE Docetaxel
ChemotherapeuticAgents INCLUDE Clofarabine
Cardiotoxicity INVOLVES LowerIncidence
Hepatotoxicity CAN_BE_CAUSED_BY CytotoxicDrugs
CytotoxicDrugs CAUSE Hepatotoxicity
Susceptibility CAN_BE_ATTRIBUTED_TO Factors
Factors SUCH_AS CancerItself
Factors SUCH_AS ViralHepatitis
Factors SUCH_AS Immunosuppression
Factors SUCH_AS NutritionalDeficiency
LiverDamage CAN_BE_A_COMBINED_OUTCOME_CAUSED_BY DamageToLiverCells
LiverDamage CAN_BE_A_COMBINED_OUTCOME_CAUSED_BY HepaticSinusoidalSyndrome
LiverDamage CAN_BE_A_COMBINED_OUTCOME_CAUSED_BY Cholestasis
LiverDamage CAN_BE_A_COMBINED_OUTCOME_CAUSED_BY LiverFibrosis
Cholestasis DOES_NOT_FLOW_FROM LiverToIntestine
Nephrotoxicity CAN_BE_CAUSED_BY TumorLysisSyndrome
Nephrotoxicity CAN_BE_CAUSED_BY DirectEffectsOfDrugClearanceByTheKidneys
DifferentDrugs ARE_AFFECTED_BY DifferentPartsOfTheKidney
Toxicity MAY_BE Asymptomatic
Toxicity MAY_BE CauseAcuteKidneyInjury
Toxicity MAY_BE SeenOnBloodOrUrineTests
Ototoxicity CAN_RESULT_IN PlatinumBasedDrugs
PlatinumBasedDrugs CAN_RESULT_IN SymptomsSuchAsDizzinessAndVertigo
Children TREATED_WITH PlatinumAnalogues
Children AT_RISK_FOR_DEVELOPING HearingLoss
LessCommonSide-effects INCLUDE RedSkin
LessCommonSide-effects INCLUDE DrySkin
LessCommonSide-effects INCLUDE DamagedFingernails
LessCommonSide-effects INCLUDE DryMouth
LessCommonSide-effects INCLUDE WaterRetention
LessCommonSide-effects INCLUDE SexualImpotence
SomeMedications INDUCE AllergicReactions
SomeMedications INDUCE PseudoallergicReactions
SpecificChemotherapeuticAgents ARE_ASSOCIATED_WITH Organ-specificToxicities
Organ-specificToxicities INCLUDE CardiovascularDisease
CardiovascularDisease SUCH_AS Doxorubicin
Organ-specificToxicities INCLUDE InterstitialLungDisease
InterstitialLungDisease SUCH_AS Bleomycin
Organ-specificToxicities OCCASIONALLY SecondaryNeoplasm
SecondaryNeoplasm SUCH_AS MoppTherapyForHodgkin'sDisease
Hand-footSyndrome IS SideEffect
SideEffect TO CytotoxicChemotherapy
NutritionalProblems IS_FOUND_DURING CancerPatients
NutritionalProblems IS_FOUND_DURING ChemotherapyTreatment
Research THAT ParenteralNutrition
ParenteralNutrition HELP_WITH WeightGain
ParenteralNutrition HELP_WITH IncreasedCalorieIntake
ParenteralNutrition HELP_WITH IncreasedProteinIntake
ParenteralNutrition COMPARED_TO EnteralNutrition
Chemotherapy MAY_NOT_COMPLETELY_DESTROY Cancer
People FREQUENTLY_FAIL_TO_UNDERSTAND Limitations
Study OF People
People HAD_BEEN_NEWLY_DIAGNOSED_WITH Incurable,Stage4Cancer
MoreThanTwo-thirdsOfPeopleWithLungCancer BELIEVED ChemotherapyWasLikelyToCureTheirCancer
MoreThanFour-fifthsOfPeopleWithColorectalCancer BELIEVED ChemotherapyWasLikelyToCureTheirCancer
Blood–brainBarrier POSES Obstacle
Obstacle TO_DELIVERY_OF Chemotherapy
Chemotherapy TO Brain
Brain HAS ExtensiveSystem
ExtensiveSystem IN_PLACE_TO_PROTECT Brain
Brain FROM HarmfulChemicals
DrugTransporters CAN_PUMP_OUT Drugs
Drugs FROM Brain
Drugs FROM Brain'sBloodVesselCells
Brain'sBloodVesselCells INTO CerebrospinalFluid
Brain'sBloodVesselCells INTO BloodCirculation
Transporters PUMP_OUT MostChemotherapyDrugs
MostChemotherapyDrugs REDUCES Efficacy
Efficacy FOR BrainTumors
SmallLipophilicAlkylatingAgents SUCH_AS Lomustine
SmallLipophilicAlkylatingAgents SUCH_AS Temozolomide
SmallLipophilicAlkylatingAgents ABLE_TO_CROSS Blood–brainBarrier
NewlyFormedTumorVasculature IS PoorlyFormed
Issues WITH DrugDelivery
Resistance IS_A_MAJOR_CAUSE_OF TreatmentFailureInChemotherapeuticDrugs
CausesOfResistanceInCancer ONE_OF_WHICH_IS PresenceOfSmallPumpsOnTheSurfaceOfCancerCells
SmallPumpsOnTheSurfaceOfCancerCells ACTIVELY_MOVE ChemotherapyFromInsideTheCellToTheOutside
CancerCells PRODUCE HighAmountsOfThesePumps
HighAmountsOfThesePumps KNOWN_AS P-glycoprotein
P-glycoprotein IN_ORDER_TO_PROTECT ThemselvesFromChemotherapeutics
Medications TO_INHIBIT FunctionOfP-glycoprotein
FunctionOfP-glycoprotein ARE_UNDERGOING Investigation
DevelopmentOfMedications HAS_BEEN_DIFFICULT_DUE_TO ToxicitiesAndInteractionsWithAnti-cancerDrugs
MechanismOfResistance IS GeneAmplification
GeneAmplification A_PROCESS_IN_WHICH MultipleCopiesOfAGeneAreProducedByCancerCells
OvercomesTheEffectOfDrugsThatReduceTheExpressionOfGenesInvolvedInReplication WITH_MORE_COPIES_OF_THE_GENE TheDrugCanNotPreventAllExpressionOfTheGene
CellCanRestoreItsProliferativeAbility DEFECTIVE_APOPTOSIS_ALLOWS SurvivalOfTheseCells
ChemotherapyDrugs KILL CancerCellsInThisManner
DefectiveApoptosis ALLOWS SurvivalOfTheseCells
ChemotherapyDrugs ALSO_CAUSE DnaDamage
UpregulationOfTheseGenes CAN_OVERCOME TheDnaDamageAndPreventTheInductionOfApoptosis
MutationsInGenesThatProduceDrugTargetProteins,SuchAsTubulin CAN_OCCUR_WHICH_PREVENT TheDrugsFromBindingToTheProtein
LeadingToResistanceToTheseTypesOfDrugs DRUGS_USED_IN_CHEMOTHERAPY CanInduceCellStress
CellStress CAN_KILL ACancerCell
TranscriptionFactorNfκb IS_THOUGHT_TO_PLAY_A_ROLE_IN ResistanceToChemotherapyInLungCancer
Cytotoxics AND TargetedTherapies
TargetedTherapies ARE NewClassOfCancerDrugs
NewClassOfCancerDrugs CAN_OVERCOME IssuesSeenWithUseOfCytotoxics
NewClassOfCancerDrugs DIVIDED_INTO TwoGroups:SmallMoleculeAndAntibodies
MassiveToxicity CAN_FREQUENTLY_BE_REDUCED_OR_ELIMINATED_WITH DueToLackOfCellSpecificityOfDrugs
Cytotoxics WILL_KILL RapidlyDividingCell
Cytotoxics WILL_KILL Tumor
Cytotoxics WILL_KILL NormalCell
TargetedTherapies ARE_DESIGNED_TO_AFFECT CellularProteinsOrProcesses
CellularProteinsOrProcesses ARE_AFFECTED_BY CancerCells
This ALLOWS HighDoseToCancerTissues
This ALLOWS LowDoseToOtherTissues
SideEffects ARE_OFTEN_LESS_SEVERE_THAN ThatSeenOfCytotoxicChemotherapeutics
TargetedTherapeutics WERE_SUPPOSED_TO_BE SolelySelectiveForOneProtein
Now IS_CLEAR ThereIsOftenARangeOfProteinTargetsThatDrugCanBind
ExampleTargetForTargetedTherapy IS Bcr-abl1ProteinProducedFromPhiladelphiaChromosome
PhiladelphiaChromosome IS_FOUND_COMMONLY_IN ChronicMyelogenousLeukemia
PhiladelphiaChromosome IS_FOUND_COMMONLY_IN SomePatientsWithAcuteLymphoblasticLeukemia
FusionProtein HAS EnzymeActivity
EnzymeActivity CAN_BE_INHIBITED_BY Imatinib
Imatinib IS SmallMoleculeDrug
MechanismOfAction IS Unknown
Cancer IS UncontrolledGrowthOfCells
Cancer COUPLED_WITH MalignantBehaviour
MalignantBehaviour INVOLVES Invasion
MalignantBehaviour INVOLVES Metastasis
Cancer CAUSED_BY InteractionBetweenGeneticSusceptibilityAndEnvironmentalFactors
InteractionBetweenGeneticSusceptibilityAndEnvironmentalFactors LEADS_TO AccumulationsOfGeneticMutations
AccumulationsOfGeneticMutations IN Oncogenes
Oncogenes CONTROL GrowthRateOfCells
AccumulationsOfGeneticMutations IN TumorSuppressorGenes
TumorSuppressorGenes HELP PreventCancer
AccumulationsOfGeneticMutations GIVE CancerCellsMalignantCharacteristics
MalignantCharacteristics INCLUDE UncontrolledGrowth
ChemotherapeuticDrugs INHIBITING Mitosis
ChemotherapeuticDrugs THAT_KILL Fast-dividingCells
Drugs CAUSE DamageToCells
Drugs TERMED Cytotoxic
Drugs PREVENT Mitosis
Drugs PREVENT MitosisByDamagingDna
Drugs PREVENT MitosisByInhibitionOfCellularMachinery
Drugs KILL CancerCells
Drugs INDUCE ProgrammedFormOfCellDeath
ProgrammedFormOfCellDeath KNOWN_AS Apoptosis
Chemotherapy AFFECTS CellDivision
Tumors HAVE GrowthRates
Tumors VARY_WIDELY_IN Chemotherapy
ProportionOfTargetedCells UNDERGOING CellDivision
Malignancies HAVE GrowthRates
Malignancies RESPOND_TO Chemotherapy
Lymphomas ARE Indolent
Lymphomas RESPOND_TO Chemotherapy
Tumours VARY_WIDELY_IN Sensitivities
SubclonalPopulations VARY_WIDELY_IN Tumor
Cells MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ImmuneSystem MAKE Contributions
ChemotherapyDrugs ARE_USED_IN DiseasesOtherThanCancer
ChemotherapyDrugs ARE_USED_IN AutoimmuneDisorders
ChemotherapyDrugs ARE_USED_IN NoncancerousPlasmaCellDyscrasia
DiseasesOtherThanCancer SUCH_AS AutoimmuneDisorders
DiseasesOtherThanCancer SUCH_AS NoncancerousPlasmaCellDyscrasia
ChemotherapyDrugs ARE_USED_AT LowerDoses
LowerDoses TO_MITIGATE SideEffectsAreMinimized
Methotrexate IS_USED_IN TreatmentOfRheumatoidArthritis
Methotrexate IS_USED_IN Psoriasis
Methotrexate IS_USED_IN AnkylosingSpondylitis
Methotrexate IS_USED_IN MultipleSclerosis
Anti-inflammatoryResponse SEEN_IN Ra
Anti-inflammatoryResponse PRIMARY_CAUSE_FOR IncreasesInAdenosine
IncreasesInAdenosine CAUSES Immunosuppression
Anti-inflammatoryResponse THOUGHT_TO_BE_DUE_TO EffectsOnImmuno-regulatoryCyclooxygenase-2EnzymePathways
Anti-inflammatoryResponse THOUGHT_TO_BE_DUE_TO ReductionInPro-inflammatoryCytokines
Anti-inflammatoryResponse THOUGHT_TO_BE_DUE_TO Anti-proliferativeProperties
Methotrexate IS_USED_TO_TREAT MultipleSclerosis
Methotrexate IS_USED_TO_TREAT AnkylosingSpondylitis
EfficacyIn DISEASES IsStillUncertain
Cyclophosphamide IS_USED_TO_TREAT LupusNephritis
LupusNephritis IS_A_COMMON_SYMPTOM_OF SystemicLupusErythematosus
Bortezomib IS_USED_TO_TREAT Cyclophosphamide
Bortezomib IS_USED_IN_COMBINATION_WITH Dexamethasone
ChemotherapyDrugs ARE_USED_IN ConditioningRegimens
ConditioningRegimens PRIOR_TO BoneMarrowTransplant
ConditioningRegimens PRIOR_TO HematopoieticStemCellTransplant
ConditioningRegimens ARE_USED_TO_SUPPRESS Recipient'sImmuneSystem
Suppress ARE_USED_TO_SUPPRESS AllowTransplantToEngraft
Cyclophosphamide IS_USED_IN Manner
Cyclophosphamide IS_USED_IN_CONJUNCTION_WITH TotalBodyIrradiation
ChemotherapeuticDrugs MAY_BE_USED_AT HighDoses
HighDoses REMOVE Recipient'sBoneMarrowCells
HighDoses REMOVE MyeloablativeConditioning
HighDoses REMOVE Non-myeloablativeAndReducedIntensityConditioning
Treatment IS_CALLED Chemotherapy
Treatment IS_OFTEN_DONE_IN TreatmentCenters
TreatmentCenters IS_OFTEN_DONE_IN PeopleWithCancer
OccupationalExposure AND SafeHandling
AntineoplasticDrugs KNOWN_AS Hazardous
AmericanSocietyOfHealth-systemPharmacists HAS_INTRODUCED ConceptOfHazardousDrugs
AmericanSocietyOfHealth-systemPharmacists PUBLISHED RecommendationIn1983
Recommendation REGARDING_HANDLING HazardousDrugs
U.s.OccupationalSafetyAndHealthAdministration FIRST_RELEASED GuidelinesIn1986
U.s.OccupationalSafetyAndHealthAdministration UPDATED GuidelinesIn1996
U.s.OccupationalSafetyAndHealthAdministration UPDATED GuidelinesIn1999
U.s.OccupationalSafetyAndHealthAdministration UPDATED GuidelinesIn2006
NationalInstituteForOccupationalSafetyAndHealth CONDUCTING Assessment
Assessment IN Workplace
Workplace REGARDING Drugs
OccupationalExposure ASSOCIATED_WITH HealthEffects
HealthEffects INCLUDING Infertility
HealthEffects INCLUDING PossibleCarcinogenicEffects
Cases REPORTED_BY NioshAlertReport
FemalePharmacist ASSOCIATED_WITH PapillaryTransitionalCellCarcinoma
Pharmacist WORKED_FOR 20Months
Pharmacist ASSOCIATED_WITH PreparingAntineoplasticDrugs
Pharmacist ATTRIBUTED_TO ExposureToAntineoplasticDrugs
Cause-and-effectRelationship ESTABLISHED_IN Literature
MalfunctionInBiosafetyCabinetry BELIEVED_TO_HAVE_EXPOSED NursingPersonnel
Investigations REVEALED_EVIDENCE_OF GenotoxicBiomarkers
AntineoplasticDrugs MAY_BE_GIVEN_ON Intravenous
AntineoplasticDrugs ARE_USUALLY_GIVEN_THROUGH Intramuscular
AntineoplasticDrugs ARE_USUALLY_GIVEN_THROUGH Intrathecal
AntineoplasticDrugs ARE_USUALLY_GIVEN_THROUGH SubcutaneousAdministration
Medication ARE_USUALLY_GIVEN_THROUGH SeveralWorkers
Medication NEEDS_TO_BE_HANDLED_BY SeveralWorkers
Worker INVOLVED_IN Handling
Worker INVOLVED_IN Preparing
Worker INVOLVED_IN Administering
Worker INVOLVED_IN CleaningObjects
Worker POTENTIALLY_EXPOSED_TO HazardousDrugs
HealthCareWorkers EXPOSED_TO Drugs
Pharmacists PREPARE AntineoplasticDrugs
PharmacyTechnicians NEEDS_TO_BE_HANDLED_BY AntineoplasticDrugs
Nurses ADMINISTER Drugs
Physicians ADMINISTER Drugs
Those RESPONSIBLE_FOR DisposingAntineoplasticDrugs
DermalExposure BELIEVED_TO_HAVE_EXPOSED MainRouteOfExposure
SignificantAmounts WERE_FOUND_IN Gloves
HealthcareWorkers BELIEVED_TO_HAVE_EXPOSED Agents
AnotherNoteworthyRouteOfExposure IS InhalationOfTheDrugs'Vapors
MultipleStudies HAVE_INVESTIGATED InhalationAsARouteOfExposure
AirSampling HAS_NOT_SHOWN DangerousLevels
It IS PotentialRouteOfExposure
IngestionByHandToMouth IS RouteOfExposure
EnforcedHygienicStandard IN HealthInstitutions
It IS PotentialRoute
One CAN_ALSO_BE_EXPOSED_TO HazardousDrugs
InjectionByNeedleSticks IS RouteOfExposure
Research CONDUCTED_IN Area
OccupationalExposure OCCURS_BY_EXAMINING_EVIDENCE_IN MultipleUrineSamplesFromHealthCareWorkers
HazardousDrugs HAVE_SHOWN HealthCareWorkers
HealthCareWorkers TO SeriousHealthRisks
Studies HAVE_SHOWN AntineoplasticDrugs
AntineoplasticDrugs HAVE_SHOWN ManySideEffects
ManySideEffects HAVE_SHOWN ReproductiveSystem
ReproductiveSystem SUCH_AS FetalLoss
ReproductiveSystem SUCH_AS CongenitalMalformation
ReproductiveSystem SUCH_AS Infertility
HealthCareWorkers WHO_ARE_EXPOSED_TO AntineoplasticDrugs
WhoAreExposedTo HAVE_SHOWN AdverseReproductiveOutcomes
AdverseReproductiveOutcomes SUCH_AS SpontaneousAbortions
AdverseReproductiveOutcomes SUCH_AS Stillbirths
AdverseReproductiveOutcomes SUCH_AS CongenitalMalformations
Studies HAVE_SHOWN ExposureToTheseDrugs
ExposureToTheseDrugs LEADS_TO MenstrualCycleIrregularities
AntineoplasticDrugs MAY_ALSO_INCREASE RiskOfLearningDisabilities
RiskOfLearningDisabilities AMONG ChildrenOfHealthCareWorkers
ChildrenOfHealthCareWorkers WHO_ARE_EXPOSED_TO HazardousSubstances
Drugs HAVE CarcinogenicEffects
Studies HAVE_SHOWN CarcinogenicEffects
Exposure TO AntineoplasticDrugs
AlkylatingAgents LINKED_WITH HumansDevelopingLeukemias
Studies HAVE_DEMONSTRATED RiskOfBreastCancer
Studies HAVE_DEMONSTRATED RiskOfNonmelanomaSkinCancer
Studies HAVE_DEMONSTRATED RiskOfCancerOfTheRectum
Nurses EXPOSED_TO Drugs
Investigations HAVE_DEMONSTRATED GenotoxicEffect
Anti-neoplasticDrugs HAVE GenotoxicEffect
Workers IN HealthCareSettings
SafeHandling IN HealthCareSettings
2018 AS_OF NoOccupationalExposureLimitsSetForAntineoplasticDrugs
AntineoplasticDrugs E.G. Osha
AntineoplasticDrugs E.G. AmericanConferenceOfGovernmentalIndustrialHygienists(acgih)
Osha HAVE_NOT_SET WorkplaceSafetyGuidelines
AmericanConferenceOfGovernmentalIndustrialHygienists(acgih) HAVE_NOT_SET WorkplaceSafetyGuidelines
Niosh RECOMMENDS_USING VentilatedCabinet
VentilatedCabinet RECOMMENDS_USING WorkerExposure
Niosh ARE_ENCOURAGED_TO_TAKE TrainingOfAllStaff
Niosh RECOMMENDS_USING UseOfCabinets
Niosh ARE_ENCOURAGED_TO_TAKE ImplementingInitialEvaluationOfTechniqueOfSafetyProgram
Niosh RECOMMENDS WearingProtectiveGloves
Niosh RECOMMENDS WearingProtectiveGowns
WearingProtectiveGloves WHEN_OPENING DrugPackaging
WearingProtectiveGloves IS_RECOMMENDED_IF Vials
WearingProtectiveGloves WHEN_LABELING DrugPackaging
One ARE_ENCOURAGED_TO_TAKE Gloves
One RECOMMENDS GlovesForPhysicalDefects
One SHOULD_ALWAYS_WEAR DoubleGloves
One SHOULD_ALWAYS_WEAR ProtectiveGowns
HealthCareWorkers REQUIRED_TO_WASH HandsWithWaterAndSoap
HealthCareWorkers REQUIRED_TO_CHANGE GlovesEvery30Minutes
HealthCareWorkers REQUIRED_TO_CHANGE GlovesWheneverPunctured
HealthCareWorkers REQUIRED_TO_DISCARD GlovesImmediatelyInChemotherapyWasteContainer
Gowns IS_USED_IN DisposableGowns
DisposableGowns MADE_OF Polyethylene-coatedPolypropylene
Individuals WEARING Gowns
Gowns HAVE LongSleeves
FinalProduct COMPLETELY_SEALED_IN PlasticBag
HealthCareWorker ARE_ENCOURAGED_TO_WASH WasteContainers
WasteContainers ARE_IN VentilatedCabinet
Workers REQUIRED_TO_DISCARD ProtectiveWear
ProtectiveWear PUT_IN Bag
Bag FOR_DISPOSAL_INSIDE VentilatedCabinet
Drugs SHOULD_BE_ADMINISTERED_USING ProtectiveMedicalDevices
ProtectiveMedicalDevices SUCH_AS NeedleLists
ProtectiveMedicalDevices SUCH_AS ClosedSystems
Techniques SUCH_AS PrimingOfIvTubing
PrimingOfIvTubing BY PharmacyPersonnel
PharmacyPersonnel IS_USED_IN VentilatedCabinet
Workers SHOULD_WEAR PersonalProtectiveEquipment
PersonalProtectiveEquipment SUCH_AS DoubleGloves
PersonalProtectiveEquipment SUCH_AS Goggles
PersonalProtectiveEquipment SUCH_AS ProtectiveGowns
Workers SHOULD_WEAR PersonalProtectiveEquipment
PersonalProtectiveEquipment WHEN_OPENING OuterBag
PersonalProtectiveEquipment WHEN_ASSEMBLING DeliverySystem
DeliverySystem TO_DELIVER Drug
Drug TO Patient
PersonalProtectiveEquipment WHEN_DISPOSING_OF AllMaterial
AllMaterial USED_IN AdministrationOfDrugs
HospitalWorkers SHOULD_NEVER_REMOVE TubingFromIvBag
IvBag CONTAINS AntineoplasticDrug
Tubing DISCONNECTING_IN System
System SHOULD_MAKE_SURE TubingHasBeenThoroughlyFlushed
Workers SHOULD_PLACE IvBagTogetherWithOtherDisposableItemsDirectlyInYellowChemotherapyWasteContainerWithLidClosed
ProtectiveEquipment SHOULD_BE_REMOVED_AND_PUT_INTO DisposableChemotherapyWasteContainer
One SHOULD_DOUBLE_BAG ChemotherapyWaste
One SHOULD_DOUBLE_BAG ChemotherapyWasteBeforeRemovingInnerGloves
One SHOULD_DOUBLE_BAG ChemotherapyWasteAfterRemovingInnerGloves
One MUST_ALWAYS_WASH One'sHandsWithSoapAndWaterBeforeLeavingDrugAdministrationSite
EmployeeTraining IS_A_TYPE_OF Training
Employees JOBS_EXPOSE_TO HazardousDrugs
Employees MUST_RECEIVE Training
Training INCLUDE ShippingAndReceivingPersonnel
Training INCLUDE Housekeepers
Training INCLUDE Pharmacists
Training INCLUDE Assistants
Training INCLUDE IndividualsInvolvedInTransportationAndStorageOfAntineoplasticDrugs
Individuals SHOULD_RECEIVE Information
Individuals SHOULD_RECEIVE Training
Information INFORM HazardsOfDrugsPresentInWorkAreas
Training INFORM HazardsOfDrugsPresentInWorkAreas
Individuals SHOULD_RECEIVE OperationsAndProceduresInWorkAreas
Individuals SHOULD_BE_TRAINED_ON MethodsUsedToDetectPresenceOfHazardousDrugs
Individuals SHOULD_BE_TRAINED_ON HowHazardsAreReleased
Individuals SHOULD_BE_TRAINED_ON PhysicalAndHealthHazardsOfDrugs
PhysicalAndHealthHazardsOfDrugs INCLUDE ReproductiveAndCarcinogenicHazardPotential
Individuals SHOULD_BE_TRAINED_ON MeasuresToAvoidAndProtectFromHazards
Information PROVIDED_WHEN HealthCareWorkersComeIntoContactWithDrugs
HealthCareWorkers SHOULD_BE_TRAINED_ON InitialAssignmentInWorkAreaWithHazardousDrugs
Training PROVIDED_WHEN NewHazardsEmerge
Training PROVIDED_WHEN NewDrugsIntroduced
Training PROVIDED_WHEN NewProceduresIntroduced
Training PROVIDED_WHEN NewEquipmentIntroduced
Housekeeping AND WasteDisposal
PerformingCleaning DECONTAMINATING WorkArea
WorkArea WHERE AntineoplasticDrugsAreUsed
WorkArea ENSURE SufficientVentilation
SufficientVentilation PREVENT BuildupOfAirborneDrugConcentrations
HospitalWorkers USE DeactivationAndCleaningAgents
HospitalWorkers USE DoubleProtectiveGloves
HospitalWorkers USE DisposableGowns
Employees SHOULD_BE_REMOVED_AND_PUT_INTO ItemsUsedInTheActivity
ItemsUsedInTheActivity IN YellowChemotherapyWasteContainer
Employees REMOVE Gloves
Employees WASH HandsWithSoapAndWater
Anything COME_INTO_CONTACT AntineoplasticDrugs
Anything HAVE TraceOfAntineoplasticDrugs
Anything PUT_IN ChemotherapyWasteContainer
WrittenPolicy NEEDS_TO_BE_IN_PLACE_IN_CASE_OF SpillOfAntineoplasticProducts
Policy SHOULD_ADDRESS PossibilityOfVariousSizesOfSpills
Policy SHOULD_ADDRESS ProcedureAndPersonalProtectiveEquipmentRequiredForEachSize
TrainedWorker SHOULD_HANDLE LargeSpill
TrainedWorker SHOULD_BE_REMOVED_AND_PUT_INTO CleanupMaterials
CleanupMaterials IN ChemicalWasteContainer
CleanupMaterials NOT_IN YellowChemotherapyWasteContainer
CleanupMaterials ACCORDING_TO EpaRegulations
OccupationalHealthProfessionals NEED_TO_ASK_FOR DetailedHistory
OccupationalHealthProfessionals NEED_TO_DO ThoroughPhysicalExam
OccupationalHealthProfessionals NEED_TO_ASK_FOR Urine
Urine DO UrineDipstick
Urine DO MicroscopicExamination
Urine LOOKING_FOR Blood
AntineoplasticDrugs KNOWN_TO_CAUSE BladderDamage
UrinaryMutagenicity THAT ExposureToAntineoplasticDrugs
ExposureToAntineoplasticDrugs WAS_FIRST_USED_BY FalckAndColleagues
ExposureToAntineoplasticDrugs USES BacterialMutagenicityAssays
Test SUCH_AS ExtraneousFactors
ExtraneousFactors SUCH_AS DietaryIntake
ExtraneousFactors SUCH_AS Smoking
Test IS Nonspecific
Test IS UsedSparingly
Test PLAYED_A_SIGNIFICANT_ROLE_IN_CHANGING UseOfHorizontalFlowCabinetsToVerticalFlowBiologicalSafetyCabinets
UseOfHorizontalFlowCabinetsToVerticalFlowBiologicalSafetyCabinets DURING PreparationOfAntineoplasticDrugs
Former EXPOSED HealthCareWorkersToHighLevelsOfDrugs
This CHANGED HandlingOfDrugs
This CHANGED EffectivelyReducedWorkersExposureToAntineoplasticDrugs
Biomarkers INCLUDE UrinaryPlatinum
Biomarkers INCLUDE Methotrexate
Biomarkers INCLUDE UrinaryCyclophosphamide
Biomarkers INCLUDE Ifosfamide
Biomarkers INCLUDE UrinaryMetaboliteOf5-fluorouracil
Drugs IS_USED_IN DrugsDirectlyInTheUrine
Measurement THAT HighExposureLevels
Measurement IS_A_SIGN_OF UptakeOfTheDrugs
UptakeOfTheDrugs HAPPENING_THROUGH Inhalation
UptakeOfTheDrugs HAPPENING_THROUGH Dermally
There IS ExtensiveListOfAntineoplasticAgents
SeveralClassificationSchemes HAVE_BEEN_USED_TO_SUBDIVIDE Medicines
Medicines IS_USED_IN Cancer
Cancer SUBDIVIDE_INTO SeveralDifferentTypes
FirstUseOfSmall-moleculeDrugs FOR Cancer
FirstUseOfSmall-moleculeDrugs WAS_IN Early20thCentury
SpecificChemicals KNOWN_TO_CAUSE Purpose
MustardGas RESULTED_IN ChemicalWarfareAgent
MustardGas KNOWN_TO_CAUSE PotentSuppressorOfHematopoiesis
FamilyOfCompounds KNOWN_AS NitrogenMustards
NitrogenMustards STUDIED_FURTHER_DURING WorldWarIi
Agent KNOWN_TO_CAUSE RapidlyGrowingWhiteBloodCells
Agent KNOWN_TO_CAUSE SimilarEffectOnCancer
SeveralPeopleWithAdvancedLymphomas RESULTED_IN DrugByVein
Improvement RESULTED_IN Remarkable
SeveralHundredPeople RESULTED_IN MustardGas
Survivors FOUND_TO_HAVE VeryLowWhiteBloodCellCounts
Experiences CONVERGED_AND_LED ResearchersToLookForOtherSubstances
FirstChemotherapyDrug DEVELOPED_FROM LineOfResearch
ManyOtherDrugs HAVE_BEEN_DEVELOPED_TO_TREAT Cancer
DrugDevelopment EXPLODED_INTO Multibillion-dollarIndustry
PrinciplesAndLimitationsOfChemotherapy DISCOVERED_BY EarlyResearchers
WordChemotherapy REFERS_TO CancerTreatment
Term COINED_BY PaulEhrlich
Term IS_USED_TO_TREAT UseOfChemicalsToTreatAnyDisease
UseOfChemicals IS_USED_TO_TREAT Disease
UseOfChemicals IS_USED_TO_TREAT Antibiotics
Ehrlich OPTIMISTIC EffectiveChemotherapyDrugsWouldBeFoundForTreatmentOfCancer
Arsphenamine DISCOVERED_IN 1907
Arsphenamine IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent ARSENIC_COMPOUND_DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent ARSENIC_COMPOUND_DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent ARSENIC_COMPOUND_DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent ARSENIC_COMPOUND_DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent ARSENIC_COMPOUND_DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent ARSENIC_COMPOUND_DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
FirstModernChemotherapeuticAgent ARSENIC_COMPOUND_DISCOVERED_IN 1907
FirstModernChemotherapeuticAgent IS_USED_TO_TREAT Syphilis
TargetedDeliveryVehicles ARE Vehicles
DeliveryVehicles MAY_AIM_TO EffectiveLevelsOfChemotherapy
DeliveryVehicles AIM_TO_REDUCE EffectiveLevelsForOtherCells
IncreasedTumorKill RESULT_IN DeliveryVehicles
ReducedToxicity RESULT_IN DeliveryVehicles
Antibody-drugConjugates ARE TherapeuticAgents
Antibody-drugConjugates COMPRISE Antibody
Antibody-drugConjugates COMPRISE Drug
Antibody-drugConjugates COMPRISE Linker
Antibody TARGETED_AT Protein
Protein EXPRESSED_IN TumourCells
Protein EXPRESSED_IN Cells
Cells UTILISE Tumor
Cells UTILISE BloodVesselEndothelialCells
Antibody-drugConjugates BIND_TO TumorAntigen
Antibody-drugConjugates INTERNALISED_IN Cell
Linker HAPPENING_THROUGH Drug
DeliveryVehicles HAPPENING_THROUGH Stability
DeliveryVehicles VARY_IN Selectivity
DeliveryVehicles HAPPENING_THROUGH MaximumEffectiveDose
MaximumEffectiveDose HAPPENING_THROUGH TumorCells
ReducedSystemicToxicity MEANS TheyCanBeUsedInPeople
They CARRY ChemotherapeuticAgents
ChemotherapeuticAgents HAPPENING_THROUGH TraditionalSystemicApproaches
FirstApprovedDrug WAS GemtuzumabOzogamicin
GemtuzumabOzogamicin RELEASED_BY Wyeth
Wyeth NOW Pfizer
Drug FOR AcuteMyeloidLeukemia
BrentuximabVedotin GRANTED AcceleratedApproval
AcceleratedApproval IS_USED_TO_TREAT RefractoryHodgkin'sLymphoma
AcceleratedApproval IS_USED_TO_TREAT SystemicAnaplasticLargeCellLymphoma
Nanoparticles ARE 1–1000Nanometer(nm)SizedParticles
Nanoparticles CAN_PROMOTE TumorSelectivity
Nanoparticles FIND_USE_IN Low-solubilityDrugs
Nanoparticles CAN_BE_TARGETED Passively
Nanoparticles CAN_BE_TARGETED Actively
PassiveTargeting EXPLOITS DifferenceBetweenTumorBloodVesselsAndNormalBloodVessels
BloodVesselsInTumors ARE "leaky"
BloodVesselsInTumors HAVE GapsFrom200To2000Nm
Gaps ALLOW NanoparticlesToEscapeIntoTheTumor
ActiveTargeting USES BiologicalMolecules
BiologicalMolecules PREFERENTIALLY_TARGET NanoparticlesToTheTumorCells
ThereAre FIND_USE_IN NanoparticleDeliverySystems
Nanoparticles MADE_OF MagneticMaterial
They FIND_USE_IN AUsefulVehicleInMagneticDrugDeliveryForPoorlySolubleAgentsSuchAsPaclitaxel
Electrochemotherapy IS CombinedTreatment
CombinedTreatment INVOLVES InjectionOfChemotherapeuticDrug
InjectionOfChemotherapeuticDrug FOLLOWED_BY ApplicationOfHigh-voltageElectricPulses
ApplicationOfHigh-voltageElectricPulses LOCALLY_TO Tumor
Tumor HAPPENING_THROUGH ChemotherapeuticDrugs
ChemotherapeuticDrugs HAPPENING_THROUGH CancerCells
ChemotherapeuticDrugs CANNOT_GO_THROUGH MembraneOfCells
ChemotherapeuticDrugs HAPPENING_THROUGH MembraneOfCells
ChemotherapeuticDrugs SUCH_AS Bleomycin
ChemotherapeuticDrugs SUCH_AS Cisplatin
GreaterEffectivenessOfAntitumorTreatment HAPPENING_THROUGH Treatment
ClinicalElectrochemotherapy SUCCESSFULLY_USED_FOR TreatmentOfCutaneousAndSubcutaneousTumors
Tumors IRRESPECTIVE_OF HistologicalOrigin
Method REPORTED_AS Safe
Method REPORTED_AS Simple
Method REPORTED_AS HighlyEffective
Reports ON ClinicalUseOfElectrochemotherapy
EsopeProject ACCORDING_TO EuropeanStandardOperatingProceduresOfElectrochemotherapy
StandardOperatingProcedures PREPARED_BASED_ON Experience
Experience OF LeadingEuropeanCancerCentresOnElectrochemotherapy
NewElectrochemotherapyModalities DEVELOPED_FOR TreatmentOfInternalTumors
InternalTumors IS_USED_IN SurgicalProcedures
InternalTumors USING EndoscopicRoutes
InternalTumors USING PercutaneousApproaches
PercutaneousApproaches HAPPENING_THROUGH TreatmentArea
HyperthermiaTherapy IS HeatTreatmentForCancer
HeatTreatmentForCancer CAN_BE PowerfulTool
HeatTreatmentForCancer USED_IN_COMBINATION_WITH Chemotherapy
HeatTreatmentForCancer USED_IN_COMBINATION_WITH Radiation
Chemotherapy THERMOCHEMOTHERAPY Radiation
Chemotherapy IS_USED_TO_TREAT ControlOfVarietyOfCancers
Heat IS_USED_TO_TREAT TumorSite
TumorSite DILATE BloodVesselsToTumor
BloodVesselsToTumor ALLOWING MoreChemotherapeuticMedicationToEnterTumor
TumorCellMembrane BECOME MorePorous
MorePorous ALLOWING MoreChemotherapeuticMedicineToEnterTumorCell
Hyperthermia HELP_PREVENT Chemo-resistance
Hyperthermia HELP_WITH Chemo-resistance
Chemo-resistance DEVELOPS_OVER Time
Tumors ADAPT ToxicityOfChemoMedication
OvercomingChemoresistance STUDIED_WITHIN Past
Cddp-resistantCells USED_IN Studies
Drug-resistantCells USED_IN_CONJUNCTION_WITH EffectiveTherapy
Chemotherapy USED_IN_CONJUNCTION_WITH Hyperthermia
Chemoresistance USED_IN_CONJUNCTION_WITH AdditionOfHeat
MitomycinC ASSOCIATED_WITH Chemoresistance
Anthracyclines ASSOCIATED_WITH Chemoresistance
Bcnu ASSOCIATED_WITH Chemoresistance
Melphalan ASSOCIATED_WITH Chemoresistance
Cddp ASSOCIATED_WITH Chemoresistance
Chemotherapy IS_USED_IN VeterinaryMedicine
Chemotherapy IS_USED_IN HumanMedicine
VeterinaryMedicine SIMILAR_TO HumanMedicine
